Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Double-Blind, Placebo-Controlled, Multicenter Extension Study (From Study OB-303 [NCT00553787]) to Determine the Safety and Efficacy Of VI-0521 for the Long-Term Treatment Of Obesity in Adults With Obesity-Related Co-Morbid Conditions

Next Previous
X
Search
Trial Profile

A Phase 3, Double-Blind, Placebo-Controlled, Multicenter Extension Study (From Study OB-303 [NCT00553787]) to Determine the Safety and Efficacy Of VI-0521 for the Long-Term Treatment Of Obesity in Adults With Obesity-Related Co-Morbid Conditions

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 10 Dec 2021

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Phentermine/topiramate (Primary)
  • Indications Obesity
  • Focus Registrational; Therapeutic Use
  • Acronyms SEQUEL
  • Sponsors VIVUS

    • Most Recent Events

    • 07 Oct 2019 According to an VIVUS media release, under the decentralized MAA procedure, the regulatory authorities in each of the Concerned Member States may simultaneously provide Marketing Authorization for use of a product within those specific countries. The company anticipates the completion of the MAA assessment and, if approved, Marketing Authorizations to begin in the second half of 2020.
    • 07 Oct 2019 According to an VIVUS media release, the European regulatory agencies in Sweden, Denmark, Finland, Iceland, Norway, and Poland have accepted the Marketing Authorization Application (MAA) for Qsymia(phentermine and topiramate extended-release) on a decentralized basis, with Sweden acting as the lead Concerned Member State,for purposes of assessing the MAA.
    • 02 May 2017 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top